Post-marketing surveillance of Levofloxacin 0.5% ophthalmic solution for external ocular infections

Kanda Y., Kayama T., Okamoto S., Hashimoto M., Ishida C., Yanai T., Fukumoto M., Kunihiro E.

2012
Drugs in R and D

View publication

Therapeutic Area

Front of the eye (FOTE)
Categories

Clinical development

Affiliations

Post-Marketing Surveillance Group, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Drug Safety Information Group, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Safety Vigilance Group, Santen Pharmaceutical Co., Ltd., 3-9-19 Shimo-Shinjo, Osaka 533-8651, Japan

Related Publications

The FAST Study: Examining Quality of Vision Outcomes in Dry Eye Disease Patients with Severe Keratitis Treated with the Ciclosporin A Cationic Emulsion

Pisella P.-J., Mourad A., Ismail D., Garrigue J.-S., Cochener B.

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.

Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.

View all Front of the eye (FOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022